gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Dihydropyrimidine dehydrogenase

dihydropyrimidine dehydrogenase
Top mentioned proteins: HAD, CAN, Orotate Phosphoribosyltransferase, POLYMERASE, ACID
Papers on dihydropyrimidine dehydrogenase
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
Schellens et al., Utrecht, Netherlands. In J Clin Oncol, Feb 2016
A polymorphism in the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie, DPYD*2A) is strongly associated with fluoropyrimidine-induced severe and life-threatening toxicity.
Purification and characterization of dihydropyrimidine dehydrogenase enzyme from sheep liver and determination of the effects of some anaesthetic and antidepressant drugs on the enzyme activity.
Gulcin et al., Artvin, Turkey. In J Enzyme Inhib Med Chem, Feb 2016
UNASSIGNED: Dihydropyrimidine dehydrogenase (DPD, E.C. was purified from sheep liver with a yield of 16.7%, purification fold of 407.5 and specific activity of 0.705 EU/mg proteins.
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Hyodo et al., Tokyo, Japan. In Int J Clin Oncol, Feb 2016
BACKGROUND: The Randomized Phase III Study Comparing Oxaliplatin plus S-1 with Cisplatin plus S-1 in Chemotherapy-naïve Patients with Advanced Gastric Cancer (G-SOX) showed the noninferiority of S-1 (an oral fluoropyrimidine-derivative dihydropyrimidine dehydrogenase inhibitor) plus oxaliplatin combination therapy (SOX) to S-1 plus cisplatin therapy (CS) in overall survival [hazard ratio (HR) from proportional hazard model 0.958, 95 % confidence interval (CI) 0.803-1.142;
Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism.
Du et al., Beijing, China. In Life Sci, Feb 2016
Also, combined luteolin and 5-fluorouracil could significantly decrease the dihydropyrimidine dehydrogenase.
TAS-102 an Emerging Oral Fluoropyrimidine.
Saif et al., Australia. In Anticancer Res, Jan 2016
Various approaches have been used to improve the efficacy of 5-FU including inhibition of its degradation enzyme dihydropyrimidine dehydrogenase (DPD) such as S1, UTF, use of 5-FU pro-drug capecitabine to exploit thymidine phosphorylase (TP) and supplementation of reduced folate acid to increase cytotoxicity.
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Gelderblom et al., Leiden, Netherlands. In Eur J Cancer, Jan 2016
They are inactivated in the liver by the enzyme dihydropyrimidine dehydrogenase (DPD).
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Fukushima et al., Tokyo, Japan. In Int J Mol Med, Jan 2016
In this study, primary tumors obtained from 1,129 patients with colorectal cancer were used to measure the mRNA expression levels of the following genes associated with the effects of standard chemotherapy for colorectal cancer: 5-fluorouracil (5-FU)-related thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD) and thymidine phosphorylase (TYMP); folate-related dihydrofolate reductase (DHFR), folylpolyglutamate synthase (FPGS) and gamma-glutamyl hydrolase (GGH); irinotecan-related topoisomerase I (TOP1); oxaliplatin-related excision repair cross-complementing 1 (ERCC1); biologic agent-related vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Schellens et al., Amsterdam, Netherlands. In Lancet Oncol, Dec 2015
BACKGROUND: The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the gene encoding DPD (DPYD), including DPYD*2A and c.2846A>T.
Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Haller et al., Halle, Germany. In J Clin Oncol, Dec 2015
Low tumor expression of dihydropyrimidine dehydrogenase may be predictive for XELOX efficacy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS HR was 2.45 (95% CI, 1.55 to 3.86; P < .001),
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.
Peters, Amsterdam, Netherlands. In Ther Adv Med Oncol, Nov 2015
TAS-102 also follows an alternative activation pathway via thymidine kinase, and is not a substrate for dihydropyrimidine dehydrogenase.
Impairment of energy metabolism in cardiomyocytes caused by 5-FU catabolites can be compensated by administration of amino acids.
Feuer et al., In Conf Proc Ieee Eng Med Biol Soc, Aug 2015
Research often focus on dihydropyrimidine dehydrogenase (DPYD) deficiency in this context.
The role of Reg IV in colorectal cancer, as a potential therapeutic target.
Zhang et al., Hangzhou, China. In Contemp Oncol (pozn), 2014
Reg IV treatment inhibits 5-fluorouracil induced apoptosis, at least two mechanisms are involved in inhibition of apoptosis by Reg IV, including Bcl-2 and dihydropyrimidine dehydrogenase (DPD).
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Xi et al., Taiyuan, China. In Int J Clin Exp Pathol, 2014
Of these enzymes, thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD) are known to play important roles in the efficacy of therapeutic agents.
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Gianni et al., Milano, Italy. In J Clin Oncol, 2010
Ridaforolimus influenced the metabolism of fluoropyrimidines and inhibited dihydropyrimidine dehydrogenase, behavior similar to that of rapamycin.
Impact of age, sex, and comorbidity on cancer therapy and disease progression.
Hurria et al., Duarte, United States. In J Clin Oncol, 2010
Biologic features can also vary by sex; several biomarkers with either prognostic or predictive value (ie, excisionrepair cross-complementation group 1 expression, epidermal growth factor receptor mutation, or dihydropyrimidine dehydrogenase polymorphism) may differentiate efficacy or toxicity in males and females.
Regulation of dihydropyrimidine dehydrogenase gene expression in regenerating mouse liver.
Ikenaka et al., Okazaki, Japan. In Int J Oncol, 2003
DPD gene expression is regulated first at the mRNA level when the hepatocytes enter the cell cycle. There is little regulation at the translational level. Cell proliferation rate is influences the enzyme activity modification.
share on facebooktweetadd +1mail to friends